Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 38 5 IN PLASTIC CONTAINER versus DEXTROSE 40 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: DEXTROSE 38 5 IN PLASTIC CONTAINER versus DEXTROSE 40 IN PLASTIC CONTAINER.
DEXTROSE 38.5% IN PLASTIC CONTAINER vs DEXTROSE 40% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose is a simple sugar that provides caloric support and serves as a source of energy. It increases blood glucose levels, which is essential for cellular metabolism, particularly in the brain and erythrocytes.
Dextrose is a monosaccharide that serves as a substrate for cellular energy production via glycolysis and the citric acid cycle. It increases blood glucose levels, providing an immediate source of calories and carbohydrate for patients with hypoglycemia or caloric needs.
Intravenous administration. Dose depends on clinical condition; typically 50-100 mL of 38.5% dextrose (19.25-38.5 g glucose) for hypoglycemia. Maximum infusion rate: 0.5 g/kg/h.
Adults: 50 mL (20 g dextrose) intravenously as a single dose for hypoglycemia; may repeat if needed. For hyperkalemia with insulin: 25 g (62.5 mL) IV with 10 units regular insulin.
None Documented
None Documented
~30 minutes (endogenous glucose turnover; clinical context: continuous infusion required for maintenance as glucose is rapidly metabolized)
30-60 minutes; clinical context: rapid redistribution and metabolism limit hyperglycemic effect, but in glucose-6-phosphatase deficiency or hepatic impairment, half-life may extend to 2-4 hours.
100% renal (excreted as carbon dioxide and water after metabolism; negligible unchanged glucose in urine under normoglycemia; renal threshold ~180 mg/dL)
Dextrose is completely metabolized to carbon dioxide and water; less than 5% is excreted unchanged in urine. Renal excretion accounts for <5% of elimination; biliary/fecal elimination is negligible.
Category C
Category C
IV Fluid
IV Fluid